Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

UTI Bacteria’s “Superglue” Secrets Revealed

Scientists at La Trobe University and the University of Queensland describe in Nature Communications how proteins in the outer membrane of bacteria are able to stick to and populate parts of the human body. This new information paves the way for the developmen

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Scientists at La Trobe University and the University of Queensland describe in Nature Communications how proteins in the outer membrane of bacteria are able to stick to and populate parts of the human body. This new information paves the way for the development of innovative treatments for preventing and curing infections, in what could be a significant step forward for new antimicrobial development, according to the researchers.

Their study (“Unique structural features of a bacterial autotransporter adhesin suggest mechanisms for interaction with host macromolecules”) focused on UpaB, the “superglue” protein of uropathogenic E. coli known to cause urinary tract infections within 50% of women within their lifetime. Similar proteins are found in the outer membrane of other pathogens responsible for infections ranging from life-threatening food poisoning to whooping cough, meningitis, typhus fever, and chlamydia.

“Autotransporters are the largest family of outer membrane and secreted proteins in Gram-negative bacteria. Most autotransporters are localized to the bacterial surface where they promote colonization of host epithelial surfaces. Here we present the crystal structure of UpaB, an autotransporter that is known to contribute to uropathogenic E. coli (UPEC) colonization of the urinary tract. We provide evidence that UpaB can interact with glycosaminoglycans and host fibronectin,” the investigators wrote.

“Unique modifications to its core β-helical structure create a groove on one side of the protein for interaction with glycosaminoglycans, while the opposite face can bind fibronectin. Our findings reveal far greater diversity in the autotransporter β-helix than previously thought, and suggest that this domain can interact with host macromolecules. The relevance of these interactions during infection remains unclear.”

Lead researcher at La Trobe University, Begoña Heras, PhD, said the study provides unprecedented fundamental science that could inform future solutions to the world health crisis in antibiotic resistance.

“The knowledge we now have on this bacteria’s protein gives us the ability to block the bacteria sticking to different parts of the human body,” she explained. “Antibiotic resistance is an urgent, global problem and this information gives us an important opportunity to develop new antimicrobial treatments. Naturally, this is the next step for this research.”

La Trobe researcher Jason Paxman, PhD, added that there is a flip-side to these bacterial proteins in that they could be harnessed for good.

“There is nothing like these bacterial proteins in modern medicine; bacteria have had thousands of years to develop these adhesive proteins,” said Paxman. “These findings could open up new opportunities such as delivering targeted therapies to parts of the human body, which could even help in the fight against cancer down the line.”

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
02How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →